Aripiprazole versus placebo for schizophrenia

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2007, Pages

  Belgamwar, Ravindra B ^a   El Sayeh, H G G ^b  

^a Staffordshire   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; PLACEBO;

CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE SEVERITY; HUMAN; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOSIS; RANDOMIZATION; RATING SCALE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; TREATMENT OUTCOME;

EID: 44949133230     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006622     Document Type: Review

References (35)

1. Abilify 2006 Product information. abilify.com.
2. Altman 1996 Altman DG, Bland JM. Detecing skewness from summary information. BMJ 1996;313:1200.
3. Anath 2003 Anath J, Venkatesh R, Burgoyne K, Augustines D, Corpuz V, Gunatilake S. Weight gain associated with atypical antipsychotic drugs: mechanisms and management. Expert Review of Neurotherapeutics 2003;3(1):59-68.
4. Andreason 1985 Andreason NC. Negative syndrome in schizophrenia: strategies for long-term management. Advances in Biochemical Psychopharmacology 1985;40:1-7.
5. Arnt 1998 Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1988;18:63-101.
6. Bland 1997 Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
7. Boissel 1999 Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
8. Burris 2002 Burris KD, Molski TF, Xu C, et al.Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. Journal of Pharmacology and Experimental Therapeutics 2002;302(1):381-9.
9. Carpenter 1994 Carpenter WT Jr, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681-90.
10. Christison 1991 Christison GW, Kirch DG, Wyatt RJ. When symptoms persist: choosing among alternative somatic symptoms for schizophrenia. Schizophrenia Bulletin 1991;17:217-45.
11. Crow 1980 Crow TJ. Positve and negative schizophrenic symptoms and the role of dopamine. British Journal of Psychiatry 1980;137:383- 6.
12. Davis 1977 Davis JM, Casper R. Antipsychotic drugs: clinical pharmacology and therapeutic use. Drugs 1977;14:260-82.
13. Deeks 2000 Deeks J. Issues in the selection for meta-analyses of binary data. Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa. 2000.
14. Divine 1992 Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
15. Donner 2002 Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
16. El-Sayeh 2006 El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 2.Art. No.: CD004578. DOI:10.1002/14651858.CD004578.pub3.
17. FDA 2002a U.S. Federal Drug Administration CDER. Abilify (aripiprazole) tablets, medical review. www.fda.gov/cder/foi/nda/2002/21- 436_Abilify.htm 2002 2002.
18. Gelder 2001 Gelder M, Lopez-Ibor jnr JJ, Andreason NC. Antipsychotic and anticholinergic drugs. New Oxford Textbook of Psychiatry, 2001:1314-16.
19. Grunder 2006 Grunder G, Kungel M, Ebrecht M, et al.Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry 2006;39(Suppl. 1):S21-5 S21-5.
20. Gulliford 1999 Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
21. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
22. Higgins 2005 Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. The Cochrane Library 2005, issue Issue 3.
23. Jadad 1996 Jadad A, Moore A, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
24. Kane 1990 Kane JM. Treatment programme and long term outcome in chronic schizophrenia. Acta Psychiatrica Scandinavica 1990;358 (suppl):151-7.
25. Kane 1993 Kane JM. Treatment programme and long term outcome in chronic schizophrenia. Acta Psychiatrica Scandinavica 1993;46:585-93.
26. Kay 1987 Kay SR. Positive and negative symptom (PANNS) scale manual. Schizophrenia Bulletin 1987;13:261-78.
27. Leucht 2005a Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale Scores. British Journal of Psychiatry 2005;187:366-71.
28. Leucht 2005b Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. What does the PANSS mean?. Schizophrenia Research 2005;79:231-8.
29. Marshall 2000 Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M. Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?. British Journal of Psychiatry 2000;176:249-52.
30. McQuade 2002 McQuade RD, Burris KD, Jordan S, et al.Aripiprazole: a dopamine-serotonin systemstabilizer. International Journal of Neuro-psychopharmacology 2002;5(Suppl. 1):S176.
31. Meltzer 1992 Meltzer HY. Treatment of the neuroleptic- nonresponsive schizophrenic patient. Schizophrenia Bulletin 1992;18:515-42.
32. Overall 1962 Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812.
33. Rivas-Vasquez 2003 Rivas-Vasquez RA. Aripiprazole: A novel antipsychotic with dopamine stabilising properties. Professional Psychology: Research and Practice 2003;34(1):108-11.
34. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
35. Ukoumunne 1999 Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):3-92. [MEDLINE: 10982317].